# CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

> **NCT03986463** · — · COMPLETED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 40 (actual)

## Conditions studied

- Lung Neoplasms
- Lung Cancer
- Neoplasm of Lung
- Non Small Cell Lung Cancer

## Interventions

- **OTHER:** Circulating tumour DNA (ctDNA)

## Key facts

- **NCT ID:** NCT03986463
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03986463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03986463, "CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03986463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*